194 related articles for article (PubMed ID: 29655795)
1. Enhanced oral absorption of sorafenib via the layer-by-layer deposition of a pH-sensitive polymer and glycol chitosan on the liposome.
Zhao M; Lee SH; Song JG; Kim HY; Han HK
Int J Pharm; 2018 Jun; 544(1):14-20. PubMed ID: 29655795
[TBL] [Abstract][Full Text] [Related]
2. pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery.
Yao Y; Su Z; Liang Y; Zhang N
Int J Nanomedicine; 2015; 10():6185-97. PubMed ID: 26491291
[TBL] [Abstract][Full Text] [Related]
3. PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure.
Mo L; Song JG; Lee H; Zhao M; Kim HY; Lee YJ; Ko HW; Han HK
Nanomedicine; 2018 Feb; 14(2):557-567. PubMed ID: 29248675
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
Cervello M; Pitarresi G; Volpe AB; Porsio B; Balasus D; Emma MR; Azzolina A; Puleio R; Loria GR; Puleo S; Giammona G
J Control Release; 2017 Nov; 266():47-56. PubMed ID: 28917533
[TBL] [Abstract][Full Text] [Related]
5. The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism.
Wang X; Zhang X; Liu F; Wang M; Qin S
Pharm Biol; 2017 Dec; 55(1):1863-1867. PubMed ID: 28614959
[TBL] [Abstract][Full Text] [Related]
6. Ternary nanocomposite carriers based on organic clay-lipid vesicles as an effective colon-targeted drug delivery system: preparation and in vitro/in vivo characterization.
Kim HY; Cheon JH; Lee SH; Min JY; Back SY; Song JG; Kim DH; Lim SJ; Han HK
J Nanobiotechnology; 2020 Jan; 18(1):17. PubMed ID: 31964393
[TBL] [Abstract][Full Text] [Related]
7. Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: An approach for improved oral pharmacokinetics of Sorafenib.
Khan MA; Ali S; Venkatraman SS; Sohail MF; Ovais M; Raza A
Int J Pharm; 2018 May; 542(1-2):196-204. PubMed ID: 29551745
[TBL] [Abstract][Full Text] [Related]
8. TPGS-chitosome as an effective oral delivery system for improving the bioavailability of Coenzyme Q10.
Shao Y; Yang L; Han HK
Eur J Pharm Biopharm; 2015 Jan; 89():339-46. PubMed ID: 25542680
[TBL] [Abstract][Full Text] [Related]
9. Development of pH-responsive organic-inorganic hybrid nanocomposites as an effective oral delivery system of protein drugs.
Lee SH; Song JG; Han HK
J Control Release; 2019 Oct; 311-312():74-84. PubMed ID: 31487499
[TBL] [Abstract][Full Text] [Related]
10. Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system.
Han HK; Shin HJ; Ha DH
Eur J Pharm Sci; 2012 Aug; 46(5):500-7. PubMed ID: 22522117
[TBL] [Abstract][Full Text] [Related]
11. Biological evaluation of a novel sorafenib analogue, t-CUPM.
Wecksler AT; Hwang SH; Liu JY; Wettersten HI; Morisseau C; Wu J; Weiss RH; Hammock BD
Cancer Chemother Pharmacol; 2015 Jan; 75(1):161-71. PubMed ID: 25413440
[TBL] [Abstract][Full Text] [Related]
12. Preparation, Characterization and In Vitro Evaluation of Eudragit S100-Coated Bile Salt-Containing Liposomes for Oral Colonic Delivery of Budesonide.
Alghurabi H; Tagami T; Ogawa K; Ozeki T
Polymers (Basel); 2022 Jun; 14(13):. PubMed ID: 35808738
[TBL] [Abstract][Full Text] [Related]
13. Improving Oral Bioavailability of Sorafenib by Optimizing the "Spring" and "Parachute" Based on Molecular Interaction Mechanisms.
Liu C; Chen Z; Chen Y; Lu J; Li Y; Wang S; Wu G; Qian F
Mol Pharm; 2016 Feb; 13(2):599-608. PubMed ID: 26709621
[TBL] [Abstract][Full Text] [Related]
14. Enhanced oral delivery of insulin via the colon-targeted nanocomposite system of organoclay/glycol chitosan/Eudragit
Lee SH; Back SY; Song JG; Han HK
J Nanobiotechnology; 2020 Jul; 18(1):104. PubMed ID: 32711522
[TBL] [Abstract][Full Text] [Related]
15. Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma.
Thapa RK; Choi JY; Poudel BK; Hiep TT; Pathak S; Gupta B; Choi HG; Yong CS; Kim JO
ACS Appl Mater Interfaces; 2015 Sep; 7(36):20360-8. PubMed ID: 26315487
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.
Parvinian A; Casadaban LC; Hauck ZZ; van Breemen RB; Gaba RC
Diagn Interv Radiol; 2015; 21(3):235-40. PubMed ID: 25835078
[TBL] [Abstract][Full Text] [Related]
17. Nanoencapsulation of psoralidin via chitosan and Eudragit S100 for enhancement of oral bioavailability.
Yin J; Xiang C; Song X
Int J Pharm; 2016 Aug; 510(1):203-9. PubMed ID: 27154253
[TBL] [Abstract][Full Text] [Related]
18. Liposomes coated with N-trimethyl chitosan to improve the absorption of harmine in vivo and in vitro.
Chen WL; Yuan ZQ; Liu Y; Yang SD; Zhang CG; Li JZ; Zhu WJ; Li F; Zhou XF; Lin YM; Zhang XN
Int J Nanomedicine; 2016; 11():325-36. PubMed ID: 26855571
[TBL] [Abstract][Full Text] [Related]
19. Eudragit S100-Coated Chitosan Nanoparticles Co-loading Tat for Enhanced Oral Colon Absorption of Insulin.
Chen S; Guo F; Deng T; Zhu S; Liu W; Zhong H; Yu H; Luo R; Deng Z
AAPS PharmSciTech; 2017 May; 18(4):1277-1287. PubMed ID: 27480441
[TBL] [Abstract][Full Text] [Related]
20. Enhanced systemic exposure of fexofenadine via the intranasal administration of chitosan-coated liposome.
Qiang F; Shin HJ; Lee BJ; Han HK
Int J Pharm; 2012 Jul; 430(1-2):161-6. PubMed ID: 22525082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
